Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Nova Eye Medical ( (AU:EYE) ).
Nova Eye Medical Limited has reported record revenues of A$28.8 million for the fiscal year ending June 30, 2025, marking a 21% increase from the previous year. This growth is attributed to the strong performance of their iTrack™ Advance device, particularly in the US market, where sales increased by 25%. The company anticipates continued revenue growth in FY26, reflecting the growing global recognition of its technology and successful market penetration.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company specializing in the development, manufacturing, and sale of proprietary ophthalmic treatment technologies and devices. Their products, including the iTrack™ Advance and Molteno3® glaucoma drainage device, are used globally by eye surgeons to treat glaucoma. The company operates sales headquarters in Fremont, California, and has manufacturing facilities in Fremont, California, and Dunedin, New Zealand.
Average Trading Volume: 378,524
Technical Sentiment Signal: Sell
Current Market Cap: A$35.52M
See more data about EYE stock on TipRanks’ Stock Analysis page.